Bristol Myers Squibb Co. stock falls 1.15% in rough trading session

16 articles · Updated · MarketWatch · Apr 29

Shares closed at $57.59 on Wednesday, ending 8.42% below their 52-week high of $62.89 set in March.
The decline outpaced competitors, with Johnson & Johnson, Pfizer, and Abbott Laboratories also posting losses but to a lesser extent.
The drop occurred during a broadly negative market session, as the S&P 500 and Dow Jones Industrial Average both recorded declines.

As BMY's stock lags, is it a value trap or a hidden buying opportunity?

With key patents expiring, can BMY's pipeline prevent a revenue collapse?

Can a single new mental health drug justify BMY's $14 billion acquisition?

How will BMY's $2 billion cost-cutting plan impact its search for new cures?

Will government price controls crush BMY's top drug before its patent even ends?